-
- Nikolaos A. Dallas
- 1Surgical Oncology and Departments of
-
- Shaija Samuel
- 2Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
-
- Ling Xia
- 2Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
-
- Fan Fan
- 2Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
-
- Michael J. Gray
- 1Surgical Oncology and Departments of
-
- Sherry J. Lim
- 1Surgical Oncology and Departments of
-
- Lee M. Ellis
- 1Surgical Oncology and Departments of
書誌事項
- 公開日
- 2008-04-01
- DOI
-
- 10.1158/1078-0432.ccr-07-4478
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases. Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.</jats:p>
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 14 (7), 1931-1937, 2008-04-01
American Association for Cancer Research (AACR)